Walter Stummer1, Marcel A Kamp. 1. Klinik für Neurochirurgie, Heinrich-Heine-Universität, Düsseldorf, Germany. stummer@med.uni-duesseldorf.de
Abstract
PURPOSE OF REVIEW: There is still controversy surrounding the role of cytoreductive surgery in the management of malignant gliomas because randomized studies have been missing. Here we review recent data from prospective studies that provide novel arguments in support of surgery. RECENT FINDINGS: Presently available studies not only demonstrate a benefit of surgical resection of malignant gliomas compared with biopsy. Data from a randomized surgical study on a technique for identifying residual tumour intraoperatively also substantiate the beneficial role of maximal cytoreduction in patients treated by resection. Potential mechanisms appear to be linked to the removal of the therapy-resistant, hypoxic, and highly-proliferative tumour core. SUMMARY: Clinical data currently available support the use of surgery for the management of malignant glioma. Surgery improves survival and may enhance the efficacy of adjunct and adjuvant therapies.
PURPOSE OF REVIEW: There is still controversy surrounding the role of cytoreductive surgery in the management of malignant gliomas because randomized studies have been missing. Here we review recent data from prospective studies that provide novel arguments in support of surgery. RECENT FINDINGS: Presently available studies not only demonstrate a benefit of surgical resection of malignant gliomas compared with biopsy. Data from a randomized surgical study on a technique for identifying residual tumour intraoperatively also substantiate the beneficial role of maximal cytoreduction in patients treated by resection. Potential mechanisms appear to be linked to the removal of the therapy-resistant, hypoxic, and highly-proliferative tumour core. SUMMARY: Clinical data currently available support the use of surgery for the management of malignant glioma. Surgery improves survival and may enhance the efficacy of adjunct and adjuvant therapies.
Authors: Marcel A Kamp; Philipp J Slotty; Jan F Cornelius; Hans-Jakob Steiger; Marion Rapp; Michael Sabel Journal: Neurosurg Rev Date: 2016-07-09 Impact factor: 3.042
Authors: Kolbein K Kolste; Stephen C Kanick; Pablo A Valdés; Michael Jermyn; Brian C Wilson; David W Roberts; Keith D Paulsen; Frederic Leblond Journal: J Biomed Opt Date: 2015-02 Impact factor: 3.170
Authors: Julia Steinmann; Marion Rapp; Bernd Turowski; Hans-Jakob Steiger; Jan Frederick Cornelius; Michael Sabel; Marcel A Kamp Journal: Neurosurg Rev Date: 2017-06-07 Impact factor: 3.042
Authors: Michael Sabel; Johannes Knipps; Lisa Margarete Neumann; Max Kieslich; Hans-Jakob Steiger; Marion Rapp; Marcel A Kamp Journal: Neurosurg Rev Date: 2018-07-23 Impact factor: 3.042
Authors: Dennis Wirth; Kolbein Kolste; Stephen Kanick; David W Roberts; Frédéric Leblond; Keith D Paulsen Journal: Biomed Opt Express Date: 2017-07-14 Impact factor: 3.732
Authors: Birgit V Nimmervoll; Nidal Boulos; Brandon Bianski; Jason Dapper; Michael DeCuypere; Anang Shelat; Sabrina Terranova; Hope E Terhune; Amar Gajjar; Yogesh T Patel; Burgess B Freeman; Arzu Onar-Thomas; Clinton F Stewart; Martine F Roussel; R Kipling Guy; Thomas E Merchant; Christopher Calabrese; Karen D Wright; Richard J Gilbertson Journal: Clin Cancer Res Date: 2018-01-04 Impact factor: 12.531
Authors: Johannes Knipps; Igor Fischer; Lisa M Neumann; Marion Rapp; Maxine Dibué-Adjei; Christiane Freiin von Saß; Jan-Malte Placke; Hendrik-Jan Mijderwijk; Hans-Jakob Steiger; Michael Sabel; Jan-Frederick Cornelius; Marcel A Kamp Journal: Clin Exp Metastasis Date: 2019-08-02 Impact factor: 5.150